Скачать или смотреть “What’s Really Happening in MSA Clinical Trials—And What the Results Mean”

“What’s Really Happening in MSA Clinical Trials—And What the Results Mean”

Sources (for listeners who want to dig in)

Amlenetug (Lu AF82422): AMULET Phase 2 summary & Phase 3 plans; press release with primary endpoint and subgroup details.
Cision

TAK-341/MEDI1341: Phase 2 trial listings and design paper.
ClinicalTrials.gov
American Academy of Neurology

ATH434 (Alterity): 2025 topline updates and MRI/biomarker signals.
Alterity Therapeutics
+1
Neurology live

ION464 (Ionis): HORIZON Phase 1/2 updates and trial page.
Neurology live
ClinicalTrials.gov

UB-312 (Vaxxinity): Phase 1b synucleinopathy study listing.
ClinicalTrials.gov

Emrusolmin/anle138b (TEV-56286): TOPAS-MSA Phase 2 recruiting materials/abstracts.
ClinicalTrials.gov
MDS Abstracts

ONO-2808 (S1P5 agonist): Phase 2 U.S. listings and background.
ClinicalTrials.gov
Mayo Clinic

YA-101: Phase 2 trial postings and first-patient-dosed announcements.
ClinicalTrials.gov
BioSpace

AB-1005 (AAV2-GDNF gene therapy): REGENERATE-MSA-101 materials.
AskBio
+1

Ampreloxetine (nOH in MSA): Phase 3 randomized-withdrawal design.
ClinicalTrials.gov
National Ataxia Foundation

Clear negatives: Verdiperstat Phase 3 failure; rifampicin & minocycline negative RCTs.
Neurology live
PubMed
PMC